The Study
Abstract 4569: D3S-003, an orally bioavailable potent and selective dual-state inhibitor targeting both GDP- and GTP-bound KRAS G12D
This study is like testing a new key in a lock inside a lab — it works on a few types of locks in a petri dish and in mice, but we don’t know if it’ll open real doors in people yet.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made a new drug that grabs onto a broken protein (KRAS G12D) that makes cancer grow, and stops it whether it's 'on' or 'off'.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 510 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — 70% tumor response in diverse models suggests this could help many patients with KRAS G12D cancers, which are currently hard to treat.
- 2The drug worked at very low doses (nanomolar) in cancer cells and shrank tumors in mice: 70% of tumors responded, and some disappeared completely.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cancer Research
Year
2026
Authors
Jing Zhang, Tienan Wang, Robert A. Mook Jr., Haibo Xie, Shaonan Wang, Zhiqiang Zheng, Xin Xiong, Hui Wang, Zhi Jian Chen
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.